Novo Nordisk shares plunge after Wegovy-maker cuts full-year guidance
Medical and tender bottles are seen with the Novo Nordsk emblem on a background display.
Norfuto Norfuto Gety photos
Danish pharmaceutical large Novo Nordsk On Tuesday, its gross sales and income shall be diminished all year long, noting the weakest development expectations of the Weight problems in Wegov in the primary American market.
The shares decreased by 15 % at 12:11 pm London time, shortly after the announcement (7:12 am EST).
The corporate mentioned that the low expectations have been pushed by weak gross sales development predictions within the second half within the therapy of medicine within the occasion of weight reduction and the therapy of Ozambi diabetes.
“For Wegovy in america, gross sales forecast displays the continual use of the GLP-1 car, and the market enlargement is slower than anticipated,” he added in an announcement.
This can be a growing story. Please test once more for updates.
2025-07-29 11:17:00
